An­oth­er year, an­oth­er $9M in BAR­DA fund­ing for Medi­Wound; Af­ter PhI­II re­sults, Scynex­is will sub­mit NDA for oral yeast in­fec­tion drug

The Is­raeli bio­phar­ma Medi­Wound has land­ed $9 mil­lion in BAR­DA fund­ing to sup­port the BLA re­sub­mis­sion for Nexo­Brid with the FDA.

Nexo­Brid is a top­i­cal­ly-ap­plied drug that re­moves es­char in four hours with­out harm­ing healthy tis­sues sur­round­ing a se­vere burn.

Medi­Wound re­ceived $168 mil­lion in BAR­DA fund­ing back in 2015 to sup­port de­vel­op­ment and man­u­fac­tur­ing, and build up pre­pared­ness for mass ca­su­al­ty events in the US, the com­pa­ny said. The com­pa­ny land­ed an­oth­er $16.5 mil­lion in 2020 to de­vel­op Nexo­Brid fur­ther. BAR­DA and Medi­Wound have an­oth­er con­tract that sup­ports the de­vel­op­ment of Nexo­Brid as a chem­i­cal burn treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER